Trexquant Investment LP Chinook Therapeutics, Inc. Transaction History

Trexquant Investment LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $252,529 - $370,729	13,555 New	13,555 $355,000
Q2 2022 Aug 11, 2022	SELL	$12.59 - $18.8 $156,178 - $233,214	-12,405 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$12.02 - $16.69 $149,108 - $207,039	12,405 New	12,405 $203,000
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $315,750 - $497,107	-29,537 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$11.5 - $14.86 $339,675 - $438,919	29,537 New	29,537 $377,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.